Combined use of ibandronate and eldecalcitol in postmenopausal Japanese women with osteoporosis

Junichi Takada; Hiroshi Wada; Kousuke Iba; Kouichi Sasaki; Takayuki Dohke; Kumiko Kanaya; Takashi Yoshizaki; Toshihiko Yamashita
December 2016
Journal of Orthopaedic Surgery (10225536);Dec2016, Vol. 24 Issue 3, p362
Academic Journal
No abstract available.


Related Articles

  • Ibandronate (Boniva) for Treatment and Prevention of Osteoporosis in Postmenopausal Women. Ference, Jonathan D.; Wilson, Stephen A. // American Family Physician;1/15/2006, Vol. 73 Issue 2, p305 

    The article provides information on the use of ibandronate (Boniva), an oral bisphosphonate approved for the treatment and prevention of osteoporosis in women who are postmenopausal. It discusses the adverse effects of the drug based on two clinical trials. It evaluates the effectiveness of...

  • ibandronate.  // Davis's Drug Guide for Nurses, 9th edition;2005, p527 

    Provides information on ibandronate, a bone resorption inhibitor used for the treatment of postmenopausal osteoporosis. Pharmacokinetics; Contraindications and precautions; Adverse reactions and side effects; Prescribed dosage.

  • Ibandronate: A Review of its Use in the Management of Postmenopausal Osteoporosis. Frampton, James E.; Perry, Caroline M. // Drugs;2008, Vol. 68 Issue 18, p2683 

    Abstract Ibandronate (ibandronic acid; Bonviva®, Boniva®), a nitrogen-containing bisphosphonate available in once-monthly oral and quarterly intravenous formulations for intermittent administration, has been approved for the treatment of osteoporosis in postmenopausal women in the EU, the...

  • Intravenous Ibandronate in the Treatment of Osteoporosis. Croom, Katherine F.; Scott, Lesley J. // Drugs & Aging;2006, Vol. 23 Issue 12, p997 

    The article focuses on the study of intravenous ibandronate in the treatment of osteoporosis, a progressive disease characterized by decreased bone mass and disordered bone structure. The treatment aims to reduce the risk of fractures, that can be achieved by slowing bone loss and bone mass...

  • Boniva®: the new quarterly intravenous osteoporosis treatment.  // South African Pharmaceutical Journal;2014, Vol. 81 Issue 9, p34 

    The article states that the Boniva injection containing bisphosphonate and ibandronate is used for treatment of osteoporosis in postmenopausal women to reduce the risk of vertebral fractures. Ibandronate does not directly affect bone formation but selectively inhibits osteoclast activity which...

  • Oral and Intravenous Ibandronate in the Management of Postmenopausal Osteoporosis: A Comprehensive Review. Reginster, J.- Y. // Current Pharmaceutical Design;Oct2005, Vol. 11 Issue 28, p3711 

    Convenient strategies are needed for postmenopausal osteoporosis management. Current oral bisphosphonates are effective and generally well tolerated, but are hampered by strict dosing requirements. Less frequent dosing schedules are expected to improve adherence to therapy and hence outcomes....

  • Monthly ibanclronate effective for osteoporosis.  // Contemporary OB/GYN;Jun2005, Vol. 50 Issue 6, p17 

    Reports on the effectiveness of monthly ibandronate as dosing for osteoporosis, according to an interim findings from multicenter Monthly Oral Ibandronate in Ladies (MOBILE) presented in the U.S. in 2005. Number of postmenopausal women with the disease enrolled in the study; Increase in lumbar...

  • Longer-lasting Osteoporosis Drugs Sought. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;5/25/2005, Vol. 293 Issue 20, p2458 

    Focuses on drugs for osteoporosis treatment, in light of the Sixth International Symposium on Osteoporosis in April. The U.S. Food and Drug Administration's approval of a once-monthly drug called ibandronate; Types of drugs used in postmenopausal women; The inconvenience of some drugs; How...

  • Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis. In-Jin Cho; Ho-Yeon Chung; Sung-Woon Kim; Jae-Won Lee; Tae-Won Lee; Hye-Soon Kim; Sin-Gon Kim; Han Seok Choi; Sung-Hee Choi; Chan Soo Shin; Ki-Won Oh; Yong-Ki Min; Jung-Min Koh; Yumie Rhee; Dong-Won Byun; Yoon-Sok Chung; Jeong Hyun Park; Dong Jin Chung; Minho Shong; Eun-Gyoung Hong // Endocrinology & Metabolism;Sep2015, Vol. 30 Issue 3, p272 

    Background: The present study evaluated the efficacy of a combination of ibandronate and cholecalciferol on the restoration of the levels of 25-hydroxyvitamin D (25[OH]D) and various bone markers in postmenopausal women with osteoporosis. Methods: This was a randomized, double-blind,...

  • Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression. Binkley, N.; Silverman, S. L.; Simonelli, C.; Santiago, N.; Kohles, J. D.; Dasic, G.; Sunyecz, J. A. // Osteoporosis International;Sep2009, Vol. 20 Issue 9, p1595 

    Bone turnover markers such as serum C-terminal cross-linking telopeptide of type I collagen (CTX-I) can be used to assess drug efficacy in osteoporosis. This study evaluated the pattern of CTX-I suppression in postmenopausal osteoporotic women receiving ibandronate. Ibandronate decreased serum...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics